Based on the study results, official recommendations will be formulated to guide clinicians and patients in managing the discontinuation of GLP-1 medications
Common side effects during the adjustment period (typically the first 24 weeks): Mild nausea usually less intense than when first starting a GLP-1 medication Changes in appetite (some patients notice less appetite suppression early on at the starting 0.25 mg dose) Mild stomach discomfort, bloating, or constipation Injection site reactions Side effects that are less likely during the switch (compared to first-time GLP-1 use), but still possible: Significant vomiting less common given prior GLP-1 exposure, but possible Hypoglycemia particularly relevant for type 2 diabetes patients on insulin or sulfonylureas
While semaglutide and tirzepatide are both weight loss medications, they are not the same medication
By preserving lean muscle mass, Tirzepatide ensures that weight loss is primarily attributed to fat loss rather than muscle loss, supporting long-term weight maintenance and metabolic health
Access and Availability Issues: Medication Shortages The Problem: Mounjaro frequently out of stock at pharmacies Cant start or continue treatment consistently Shortages interrupt weight loss progress No guarantee when supply will return The Solution: Alternative sources may have better availability, including compounded options that arent subject to the same shortage issues
b) Thigh Injection Site The thigh is another very common injection location